Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
First diagnostic centre to open in Mohali on August 31
The company has to approach the DCGI for approval to commence the trials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
Opaganib, a leading novel small molecule investigational oral pill in development for Covid-19, is a unique host targeted, dual antiviral and anti-inflammatory drug that acts on the cause and effect of the disease
The hospital works in close collaboration with the Network for Organ Sharing and the National Organ & Tissue Transplant Organisation (NOTTO) and it is amongst the very few hospitals doing ABO-incompatible transplant
The investment will establish drug product manufacturing capacity for clinical trial and commercial supply in China and offer customers combined drug substance and drug product manufacturing services
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
It is the first branded generic alternative to Fostair 100/6 pMDI
Subscribe To Our Newsletter & Stay Updated
